title: Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
abstract: OBJECTIVE
  To investigate the outcomes of intravitreal antivascular endothelial growth factor (VEGF) therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR).
  
  
  METHODS
  Patients from four high-volume referral centres who presented with neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were included. Data retrieved from medical records and multimodal imaging were analysed.
  
  
  RESULTS
  Forty-one eyes of 38 patients (21 male, 17 female; mean age 78±8 years) were enrolled. Median follow-up was 28±19 (12-72) months with a mean of 9.2±7.4 intravitreal anti-VEGF injections per eye were administrated. Best-corrected visual acuity (BCVA) was 0.5±0.3 logMAR; it improved significantly at 1 year (0.3±0.3 logMAR; p=0.02) and returned to baseline values at last follow-up visit (0.6±0.4 logMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408±150 μm to 328±104 μm at 1 year (p=0.021) and to 335±127 μm at last follow-up visit (p=0.032). The baseline severity of DR was graded as mild non-proliferative DR (NPDR) in 21 (51%) eyes, moderate NPDR in 14 (34%), severe NPDR in 4 (10%) and inactive proliferative DR in 2 (5%). At last follow-up visit, one eye graded as moderate NPDR improved to mild, one eye graded as severe NPDR improved to mild and one eye graded as severe NPDR was inactivated due to panretinal photocoagulation.
  
  
  CONCLUSIONS
  Outcomes analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilisation of BCVA and reduction of CMT, along with stable or improved DR stage throughout follow-up.
authors.affiliation: Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Bandello
authors.affiliation: Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
authors.forename: Federico
authors.initials: F
authors.lastname: Corvi
authors.affiliation: Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: La Spina
authors.affiliation: Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Benatti
authors.affiliation: Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
authors.forename: Lea
authors.initials: L
authors.lastname: Querques
authors.affiliation: Department of Ophthalmology, Hopital Intercommunal de Creteil, University Paris Est Creteil, Cretéil, France.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Capuano
authors.affiliation: Vitreous Retina Macula Consultants of New York, New York, New York, USA.|Department of Ophthalmology, New York University School of Medicine, New York, New York, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Naysan
authors.affiliation: Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
authors.forename: Xuejing
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.|Greater Los Angeles VA Healthcare Center, Los Angeles, California, USA.
authors.forename: David
authors.initials: D
authors.lastname: Sarraf
authors.affiliation: Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
authors.forename: Maurizio Battaglia
authors.initials: MB
authors.lastname: Parodi
authors.affiliation: Department of Ophthalmology, Hopital Intercommunal de Creteil, University Paris Est Creteil, Cretéil, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Souied
authors.affiliation: Vitreous Retina Macula Consultants of New York, New York, New York, USA.|Department of Ophthalmology, New York University School of Medicine, New York, New York, USA.
authors.forename: K Bailey
authors.initials: KB
authors.lastname: Freund
authors.affiliation: Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.|Department of Ophthalmology, Hopital Intercommunal de Creteil, University Paris Est Creteil, Cretéil, France.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Querques
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D012160:Retina / Q000000981:diagnostic imaging* / Q000187:drug effects; D015861:Retinal Neovascularization / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Drugs; Macula; Retina; Treatment Medical